Stocks Health care ORKA
NASDAQ · Health careOruka Therapeutics, Inc. (ORKA)
It posted a net loss of $152.6M. In fiscal 2025 capital spending exceeded operating cash flow by $88.4M. At September 30, 2026 it held $191.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Oruka Therapeutics, Inc.
- Net worth
- Oruka Therapeutics, Inc. has a market value (market cap) of $7.2B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $0, with a net loss of $5.3M.
- Cash flow
- In fiscal 2025 operations used $88.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
What Oruka Therapeutics, Inc. does
Oruka Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORKA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$105.4M | n/a | -$88.4M |
| 2023 | $0 | -$5.3M | -$0.37 | -$5M |
| 2022 | $0 | -$9.9M | -$0.69 | -$10.9M |
| 2021 | $0 | -$19.3M | -$1.39 | -$18.8M |
| 2020 | $0 | -$9.7M | -$2.07 | -$7.7M |
| 2019 | $0 | -$5.5M | -$4.15 | -$4.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Oruka Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- October 26, 2026
- August 24, 2026
- August 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026
- August 10, 2026
Insider trades
What the people running Oruka Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $24.4M worth of shares in the last 90 days and bought none on the open market. Most of the selling (98%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Klein Lawrence OttoChief Executive Officer, Director | Exercised options | 25,000 | $195K |
| November 2, 2026 | Klein Lawrence OttoChief Executive Officer, Director | Soldpre-planned (10b5-1) | 6,466 | $612.8K |
| November 2, 2026 | Klein Lawrence OttoChief Executive Officer, Director | Soldpre-planned (10b5-1) | 15,036 | $1.4M |
| November 2, 2026 | Klein Lawrence OttoChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,442 | $236.1K |
| November 2, 2026 | Klein Lawrence OttoChief Executive Officer, Director | Soldpre-planned (10b5-1) | 756 | $73.7K |
| November 2, 2026 | Klein Lawrence OttoChief Executive Officer, Director | Soldpre-planned (10b5-1) | 300 | $29.5K |
| October 20, 2026 | Quinlan Paul TGeneral Counsel | Exercised options | 9,000 | $70.2K |
| October 20, 2026 | Quinlan Paul TGeneral Counsel | Soldpre-planned (10b5-1) | 400 | $30K |
Who owns ORKA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fairmount Funds Management LLC13D, may seek influence with 4 related filers | 19.99% | November 21, 2024 |
| Harwin Peter Evan13D, may seek influence with 4 related filers | 19.5% | July 1, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 7.4% | August 14, 2026 |
| Capital World Investors13G, passive | 5.6% | August 12, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 5.2% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 256 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 9,057,645 | +1,626,242 |
| BlackRock, Inc. | 4,990,181 | +1,463,094 |
| Venrock Adviser, LLC | 4,148,428 | 0 |
| Fairmount Funds Management LLC | 3,705,262 | 0 |
| Capital World Investors | 3,401,639 | new |
| Rtw Investments, LP | 3,139,030 | +1,080,882 |
| State Street Corp | 2,673,090 | +1,059,629 |
| Vanguard Capital Management LLC | 2,360,971 | +501,340 |
| Paradigm Biocapital Advisors LP | 2,144,526 | -175,790 |
| Deep Track Capital, LP | 1,926,000 | -108,203 |
| Bellevue Group AG | 1,657,190 | +1,150,182 |
| Franklin Resources Inc | 1,621,451 | +617,395 |
| Remedium Capital Partners, LLC | 1,565,661 | 0 |
| RA Capital Management, L.P. | 1,554,597 | new |
| Viking Global Investors LP | 1,503,478 | -1,163,212 |
| Geode Capital Management, LLC | 1,429,954 | +475,087 |
| Jupiter Topco LLC | 1,375,844 | new |
| Perceptive Advisors LLC | 1,345,063 | -50,438 |
| Polar Capital Holdings Plc | 1,228,609 | +180,916 |
| Citadel Advisors LLC | 1,119,011 | +111,474 |
Insiders
8 insiders reported holding 2,505,288 shares in total, about $274.3M at the last price.
| Holder | Shares |
|---|---|
| Fairmount Funds Management LLCDirector, 10% owner | 1,131,9541,131,954 held indirectly |
| Klein Lawrence OttoChief Executive Officer, Director | 923,128 |
| Sandler Laura LeeChief Operating Officer | 235,478 |
| Edwards Larry ToddChief Commercial Officer | 100,000 |
| Dambkowski CarlDirector | 38,743 |
| Goncalves JoanaChief Medical Officer | 31,771 |
| Quinlan Paul TGeneral Counsel | 29,995 |
| Agarwal ArjunSenior Vice President, Finance | 14,219 |
Questions about ORKA
What does Oruka Therapeutics, Inc. do?
Oruka Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ORKA. Its shares trade on NASDAQ under the ticker ORKA.
What is Oruka Therapeutics, Inc.'s net worth?
Oruka Therapeutics, Inc. has a market value (market cap) of $7.2B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Oruka Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $152.6M.
When did Oruka Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
Similar companies
Compare ORKA with
Follow ORKA
Get an email when Oruka Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Oruka Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.